

ORIGINAL PAPER

Transplantation and Cellular Therapy

Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study

Federico Stella^{1,2}  | Annalisa Chiappella²  | Martina Magni²  | Francesca Bonifazi³  | Chiara De Philippis⁴ | Maurizio Musso⁵ | Ilaria Cutini⁶  | Silva Ljevar⁷ | Anna Maria Barbui⁸ | Mirko Farina⁹ | Massimo Martino¹⁰ | Massimo Massaia¹¹ | Giovanni Grillo¹² | Piera Angelillo¹³ | Barbara Botto¹⁴ | Francesca Patriarca¹⁵ | Mauro Krampera¹⁶ | Luca Arcaini^{17,18}  | Maria Chiara Tisi¹⁹ | Pierluigi Zinzani³  | Federica Sorà²⁰ | Stefania Bramanti⁴ | Martina Pennisi² | Cristiana Carniti²  | Paolo Corradini^{1,2} 

Correspondence

Martina Magni, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, Milano 20133, MI, Italy.
Email: martina.magni@istitutotumori.mi.it

Funding information

Associazione Italiana contro le Leucemie-linfomi e mieloma" (AIL) Milano; Società Italiana di Ematologia; Italian Ministry of Health, Grant/Award Number: PNC-E3-2022-23683269-PNC-HLS-TA and PNRR-MAD-2022-12376059; Fondazione IRCCS Istituto Nazionale dei Tumori; Associazione Italiana per la Ricerca sul Cancro, Grant/Award Number: IG2024-ID.31005project-P.I. CorradiniPaolo

Summary

Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral blood monitored in 61 of them. Clinical outcomes and toxicities are consistent with previous real-world evidence studies. Notably, beyond established poor prognostic factors—such as blastoid variant and elevated lactate dehydrogenase—BTKi refractoriness and platelet count emerged as significant predictors of survival. Specifically, the 1-year overall survival was 56% in BTKi-refractory patients compared to 92% in BTKi-relapsed patients ($p=0.0001$). Our study also demonstrated that in-vivo monitoring of brexu-cel expansion is feasible and correlates with progression-free survival and toxicities. Progression-free survival at 1 year was 74% in patients categorized as strong expanders, based on brexu-cel peak concentration, versus 54% in poor expanders ($p=0.02$). Furthermore, in-vivo expansion helped identify a high-risk group of non-responders, those with progressive or stable disease at the 90-day post-infusion evaluation (OR=4.7, 95% CI=1.1–34, $p=0.04$) characterized by dismal outcomes. When integrated with other clinical factors, monitoring brexu-cel expansion could assist in recognizing patients at high risk of early relapse.

KEY WORDS

brexu-cel, CAR T-cell, in vivo expansion, mantle cell lymphoma, real world

[Correction added on 14 February 2025, after first online publication: The subcategory has been changed.]

Cristiana Carniti and Paolo Corradini contributed equally to this work.

For affiliations refer to page 649.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Author(s). *British Journal of Haematology* published by British Society for Haematology and John Wiley & Sons Ltd.

INTRODUCTION

Patients affected by mantle cell lymphoma (MCL) relapsed or refractory to Bruton tyrosine kinase inhibitors (BTKi) have a poor prognosis, with a median overall survival (OS) of less than 1 year with previous salvage therapies and a clinical course characterized by continuous relapses over time.^{1–3}

Brexucabtagene autoleucel (brexu-cel), an anti-CD19 CAR T-cell therapy, has been recently approved based on the results of the pivotal trial ZUMA-2.^{4,5} In the ZUMA-2 trial, heavily pretreated patients with MCL achieved overall response (ORR) and complete response (CR) rates of 93% and 67% respectively.⁴ The estimated 1-year progression-free survival (PFS) and OS rates were 61% and 83% respectively.⁴

Data from real-world evidence (RWE) not only confirmed the high response rates documented in the pivotal trial but also reported a shorter duration of response.^{6–10} Additionally, results from both the clinical trial and real-world evidence have documented that the prognosis of patients who partially respond or do not respond to brexu-cel therapy is very poor, with a median OS of 16.3 and 8.5 months respectively.⁵ Accurate prediction is crucial for developing early and effective consolidation strategies, which could potentially improve outcomes for these high-risk patients.

Among the previously reported real-world evidence, both the French study⁸ and the experience published by Hamilton et al.¹⁰ included in-vivo expansion data. However, both studies had small sample sizes—21 patients in the French study and 25 MCL patients in the Stanford study—limiting the significance of the findings and leaving the clinical relevance of CAR T-cell expansion unclear to date.

The aim of this study is to present real-world data from a prospective multicentre cohort of patients treated with commercial brexu-cel and to assess the impact of in-vivo expansion on outcomes.

METHODS

The CART-SIE study is an ongoing multicentre prospective observational study enrolling patients eligible for CAR T-cell therapy (as defined by the Italian drug agency) in 22 Italian centres. Patients included in this analysis were treated in 20 of these 22 centres (in the remaining centres, no patients with MCL had been treated at the time of the data cut-off). It is important to note that brexu-cel is currently the only anti-CD19 CAR T-cell therapy approved in Italy for the treatment of MCL. Consequently, all patients in this study received brexu-cel.

There is no universal consensus on the time frame that must elapse from the start of BTKi therapy to when the response is lost in order to define a patient as refractory. Consistently with previous studies¹¹ and based on established data concerning the treatment of relapsed/refractory (R/R) MCL with BTKi, showing a median time to response of 2 months and a median duration of response of 17 months,¹² in our study, BTKi-refractory patients were defined as those

whose disease either did not respond or progressed within 6 months of initiating BTKi therapy.

The study adhered to the Declaration of Helsinki and good clinical practice guidelines, obtaining ethical approval from institutional review boards at each site (ClinicalTrials.gov ID: NCT06339255). All patients gave informed consent.

Response was assessed according to the Lugano criteria.¹³ Cytokine release syndrome (CRS) and neurotoxicity were graded according to the American Society for Transplantation and Cellular Therapy consensus.¹⁴ Haematological toxicity was defined and graded based on the consensus outlined by the European Hematology Association and the European Society for Blood and Marrow Transplantation,¹⁵ specifically, late and severe immune effector cell-associated haematotoxicity (ICAHT) is defined as persistent neutropenia (at least two consecutive measurements), severe (ANC $\leq 500/\mu\text{L}$) and late (occurring more than 30 days after CAR T-cell infusion). CAR-HEMATOTOX was calculated according to Rejeski et al.¹⁶

PFS, OS and duration of response (DoR) curves were estimated using the Kaplan–Meier method. The median follow-up was calculated using the reverse censoring methodology. Between-group comparisons of Kaplan–Meier curves were carried out using the log-rank test. Cox models were used for survival outcomes, and logistic models were applied for binary outcomes.

CAR T cells were longitudinally monitored in peripheral blood (PB) through multiparameter flow cytometry (MFC) using the CD19 CAR detection reagent (Miltenyi), as previously described¹⁷ or the CD19 CAR FMC63 Idiotypic (REA1297) (Miltenyi).

RESULTS

Since 2019 to July 2024, a total of 1002 non-Hodgkin lymphoma patients were enrolled in the CART-SIE study, of whom 106 were affected by MCL. The median age of the MCL population was 63 years (42–79), 70% of patients had advanced-stage classical MCL and the entire population had been exposed to BTKi, with 35% of the population being refractory (Table 1). Bridging therapy was administered to 79% (83) of patients: 45% (37/83) continued ongoing BTKi therapy, 13% (11/83) received bendamustine-containing regimens, 13% (11/83) were treated off-label with venetoclax-containing regimens, and the remaining patients received immunochemotherapy (18%, 15/83), lenalidomide (6%, 5/83) or local radiotherapy (5%, 4/83) (Table S1).

Efficacy and outcomes

The best ORR and CR rate were 88% and 75%, respectively, while the ORR at 90 days was 77%, with a CR rate of 70%. In the univariate analysis, among baseline clinical factors, only the presence of bulky disease was significantly associated with a lower rate of complete responses (OR = 0.17,

TABLE 1 Patients' characteristics.

	Global population N= 106pts	In-vivo expansion N= 61 pts	
		Strong expander ^a N= 28pts	Poor expander ^a N= 33pts
Sex (female)	22 (21%)	3 (11%)	5 (15%)
Age (median)	63 (42–79)	60 (44–74)	65 (42–79)
Histology			
Classic MCL	74 (70%)	24 (86%)	23 (70%)
Blastoid MCL	20 (19%)	1 (4%)	5 (15%)
Pleomorphic MCL	12 (11%)	3 (11%)	5 (15%)
Refractory disease	56 (53%)	15 (45%)	17 (63%)
Previous BTKi	106 (100%)	28 (100%)	33 (100%)
BTKi relapsed	54 (65%) ^b	13 (68%) ^b	16 (62%) ^b
BTKi refractory	29 (35%) ^b	6 (32%) ^b	10 (38%) ^b
Missing data on refractoriness	23 (22%)	7 (25%)	9 (27%)
Previous ASCT	61 (58%)	16 (57%)	16 (48%)
Previous lines (median)	3 (2–5)	3 (2–5)	3 (2–5)
Stage (advanced = Ann Arbor III–IV)	96 (92%)	26 (93%)	29 (91%)
Extranodal disease	55 (52%)	16 (57%)	18 (58%)
Bone marrow involved	62 (59%)	18 (64%)	15 (48%)
Bulky disease	21 (20%)	6 (21%)	11 (33%)
LDH baseline > ULN	25 (25%) ^b	19 (76%)	23 (72%)
Missing	6 (6%)	3 (11%)	1 (3%)
sMIPI			
Low	32 (35%) ^b	9 (45%) ^b	10 (32%) ^b
Intermediate	18 (20%) ^b	6 (30%) ^b	3 (10%) ^b
High	41 (45%) ^b	5 (25%) ^b	18 (58%) ^b
Missing	15 (14%)	8 (28%)	2 (6%)
POD24	45 (42%)	17 (65%)	19 (58%)
TP53 mutated	9 (29%) ^b	4 (36%) ^b	3 (33%) ^b
Missing	75 (71%)	17 (61%)	24 (73%)
Ki-67			
>30%	36 (54%) ^b	8 (42%) ^b	11 (44%) ^b
Missing	39 (37%)	9 (32%)	8 (24%)
Bridging therapy	83 (79%)	18 (67%)	29 (88%)
Bridging continuing BTKi	39 (37%)	11 (39%)	14 (42%)
Response to bridging: no response ^c	68 (72%)	20 (74%)	21 (68%)

Abbreviations: ASCT, autologous stem cell transplantation; BTKi, Bruton tyrosine kinase inhibitors; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; POD24, progression of disease within 24 months from the completion of treatment; sMIPI, simplified Mantle Cell Lymphoma International Prognostic Index; ULN, upper limit of normal.

^aStrong and poor expander defined according to C_{MAX} (132.9 CAR+/μL). See below.

^bCalculated based on the population for which data are available.

^cDefined as Progressive disease + Stable disease after bridging therapy.

95%CI=0.05–0.53, $p=0.002$). With a median follow-up of 12.1 months (IQR: 6, 18), the 1-year OS in the global population was 82% ($_{95\%}$ CI=74%–90%), while the 1-year PFS was 62% ($_{95\%}$ CI=52%–74%) (Figure 1A,B). The duration of response at 1 year was 70% ($_{95\%}$ CI=59%–84%).

Disease assessment at day 90 confirmed its relevance in prognostic stratification with a 1-year OS of 94% for patients

in complete response compared to only 19% for those with PD ($p<0.0001$, Figure S1).

Among baseline clinical factors, histological subtype, refractoriness to BTKi, pre-lymphodepletion lactate dehydrogenase (LDH) levels and pre-lymphodepletion platelet counts were shown to be associated with both PFS and OS. Patients with blastoid MCL demonstrated inferior PFS and OS




FIGURE 1 Overall and progression-free survival: Global (A and B) and according to BTKi refractoriness (C and D). [Colour figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

compared to others (1-year OS 88% in classic vs. 78% in pleomorphic vs. 62% in blastoid, log-rank p -value=0.01, 1-year PFS 69% in classic vs. 54% in pleomorphic vs. 39% in blastoid, log-rank p -value=0.03). Similarly, survival was lower in patients refractory to prior BTKi therapy (1-year OS 92% in relapsed vs. 56% in refractory, $p=0.0001$, 1-year PFS 68% in relapsed vs. 48% in refractory, $p=0.01$, Figure 1C,D; Table S2), in those with high pre-lymphodepletion LDH levels (1-year OS 93% in LDH normal vs. 66% in LDH > ULN, $p=0.0003$, 1-year PFS 75% in LDH normal vs. 39% in LDH > ULN, $p=0.01$), and low pre-lymphodepletion platelet (PLT) counts (<75000/ μ L) (1-year OS 86% in non-thrombocytopenic vs. 70% in thrombocytopenic, $p=0.04$, 1-year PFS 67% in non-thrombocytopenic vs. 47% in thrombocytopenic, $p=0.04$). The presence of bulky disease at baseline was significantly associated with shorter PFS, but not with OS (1-year PFS 38% in bulky vs. 67% in non-bulky, $p=0.04$).

Toxicity

The incidence of CRS of any grade or grade ≥ 3 was 95%/21% while the incidence of any grade or grade ≥ 3 ICANS and 48%/18%. Platelets count >75,000/ μ L at the time of infusion was shown to be associated with lower rates of both grade ≥ 3 CRS and ICANS (CRS G > 3: OR=0.15, 95%CI=0.05–0.42, $p<0.001$; ICANS: OR=0.07, 95%CI=0–0.39, $p=0.01$). Tocilizumab was required in 84% of all patients, 54% of patients received steroids and 18% were admitted to intensive care.

Regarding haematological toxicity, the cumulative incidence of late and severe immune effector cell-associated haematotoxicity (ICAHT) was 4.4%. The incidence of severe thrombocytopenia (PLT <50 000/ μ L) and severe anaemia (Hb <8 g/dL) was 18% and 1.1% respectively. The non-relapse mortality rate was 7.3% at 1 year (range 3.2%–14%), with two of seven deaths (29%) related to bacterial infections, 1 to G5 CRS, 1 to G5 ICANS, 1 to cerebrovascular event and 2 to multi-organ failure.

Among 106 patients, 3 (2.8%) were diagnosed with secondary primary malignancies (SPM) while in complete remission for MCL, namely myelodysplastic syndromes (MDS) in two patients and bladder cancer in one patient; of note, this patient already had a diagnosis of bladder cancer more than 10 years prior to CAR T infusion and thus cannot be attributed to CAR T activity. Both patients with MDS were male, aged 57 and 52 years, respectively, and heavily pretreated (n. of previous lines of therapy: 3 and 4 respectively), with the time from brexu-cel infusion to MDS diagnosis being 3.7 and 18.7 months respectively. Both patients underwent allogeneic transplant and are currently alive and in complete remission. TP53 mutation and complex karyotype were observed in one of the two patients, consistent with a diagnosis of therapy-related neoplasm.

In-vivo expansion

In-vivo expansion data for brexu-cel were available for 61 of 106 patients (57%). Table 1 summarizes the characteristics




FIGURE 2 In-vivo brexu-cel expansion—(A) Expansion kinetics; (B) Day 90 response according to expansion; (C) ROC curve to identify a C_{MAX} cut-off with higher sensitivity (sens) and specificity (spec) in predicting day 90 response; (D) progression-free survival according to the C_{MAX} [Colour figure can be viewed at wileyonlinelibrary.com].

of the 106 total patients and the 61 with available in-vivo expansion data, showing no significant differences between the two groups. Table S3 details the efficacy in the entire cohort and in the subset for which in-vivo expansion data are available: no differences were observed between the two populations. The in-vivo expansion kinetics of brexu-cel are illustrated in Figure 2A, with a median peak CAR T-cell concentration (C_{MAX}) at the time of maximal expansion (T_{MAX}) of 117 CAR+/ μ L, a median concentration at day 10 (C_{10}) of 77.7 CAR+/ μ L and a median concentration at day 14 (C_{14}) of 76.3 CAR+/ μ L. The median area under the curve from day 0 to 30 (AUC_{0-30}) was 241.4 (range: 0–9923). Median AUC_{0-30} and C_{14} were significantly higher in day 30 responders (Figure S2), whereas only C_{10} , C_{MAX} and AUC_{0-30} but not circulating CAR T at day 7, 14, 21 and 30 were all associated with response at day 90 (Figure 2B; Figure S3). In particular, C_{10} was 128.1 CAR+/ μ L in day 90 responders (patients in CR or PR) versus 8.9 CAR+/ μ L in non-responders ($p=0.03$), C_{MAX} was 211.4 CAR+/ μ L in responders versus 53.13 CAR+/ μ L in non-responders ($p=0.03$), while AUC_{0-30} was 390.9 in responders versus 85.22 in non-responders ($p=0.02$).

Circulating CAR T cells were still detectable after the first month in a fraction of patients, although persistence is not associated with a better PFS (1-year PFS 80% for patients with ≥ 5 CAR T/ μ L at day 30 vs. 78% for patients with < 5 CAR T/ μ L, Figure S4).

A multivariable logistic model, adjusted for bulky disease, confirmed the independent effect of in-vivo expansion on complete response rates (OR = 4.7, 95% CI = 1.2–25, $p=0.03$, Table S4). Using a receiver operating characteristic (ROC) curve, a cut-off value of 132.9 CAR+/ μ L at C_{MAX} was identified, optimizing sensitivity and specificity in predicting complete response rates at 90 days (sensitivity 87.5%, specificity 56.52%, Figure 2C). Patients classified as ‘strong expanders’, defined by a $C_{MAX} > 132.9$ CAR+/ μ L, demonstrated significantly better PFS than ‘poor expanders’ (1-year PFS: 74% in strong expanders vs. 54% in poor expanders, $p=0.02$, Figure 2D). Consistently, ‘poor expanders’ showed a fourfold higher risk of being ‘non-responders’ at day 90 compared to ‘strong expanders’ (OR = 4.7, 95% CI = 1.1–37, $p=0.04$).

A multivariable Cox model for PFS was fitted, adjusting for BTKi refractoriness and PLT count before lymphodepletion, and confirmed the independent effect of in-vivo CAR T expansion (C_{MAX} strong expander: HR = 0.34, 95% CI = 0.1–1.0, $p=0.04$). In-vivo expansion of CAR T cells was also associated with severe ($G \geq 3$) CRS (OR = 4.7, 95% CI = 1.2–23, $p=0.02$). However, no statistically significant differences in CAR-T cell expansion were observed in relation to ICANS and haematological toxicity (OR for ICANS in expander = 2.31, 95% CI = 0.82–6.72, $p=0.1$).

To investigate the relationship between in-vivo expansion and BTKi refractoriness in determining response, a bivariate logistic model was developed to evaluate complete response

at 90 days. This model suggests that BTKi refractoriness exerts a similar effect on response when adjusted for in-vivo expansion, as the odds ratio (OR) in the bivariate analysis (OR=0.35 [95% CI=0.1–1.6], $p=0.2$) is comparable to that observed in the univariate analysis (OR=0.5 [95% CI=0.2–1.6], $p=0.3$) (Tables S5 and S6).

Bridging therapy was the only clinical factor correlated with the in-vivo expansion of brexu-cel. Patients who received bridging therapy exhibited significantly lower CAR T-cell expansion compared to those who did not. Among patients classified as ‘poor expanders’ 90% had received bridging therapy, while only 10% had not (OR=0.2, $_{95\%}$ CI 0.04–0.8, $p=0.02$). Multivariable logistic models confirmed the impact of bridging therapy on expansion, both in terms of C_{MAX} and AUC_{0-30} (Table S7). However, focusing on the type of treatment used for bridging therapy, no statistically significant impact on expansion was observed for regimens containing BTK inhibitors, bendamustine or BCL-2 inhibitors (Table S8).

DISCUSSION

Our prospective, observational, multicentre study represents the largest cohort of patients treated with commercial brexu-cel, incorporating in-vivo monitoring of CAR T cells. Efficacy, outcomes and toxicities were comparable to those reported in previous RWE studies.^{6–9}

In addition to the established clinical factors associated with survival of MCL patients receiving CAR T-cell therapy, such as the presence of the blastoid variant and elevated LDH levels, our study identified refractoriness to BTKi treatment and platelet count as significant prognostic factors.

The negative prognostic value of BTKi refractoriness in MCL is well established^{1,18}; however for the first time, we demonstrate its negative impact in the context of CAR T-cell therapy. Patients with BTKi-refractory MCL pose a significant therapeutic challenge due to the aggressive nature of their disease. Therefore, future studies should focus on optimizing bridging therapy and exploring earlier intervention with CAR T-cell therapy for patients showing suboptimal responses to BTK inhibitors. This is particularly relevant given the results of the TRIANGLE study,¹⁹ which will likely lead to the incorporation of BTK inhibitors starting from the first line of treatment.

The influence of platelet count on outcomes in anti-CD19 CAR T-cell treatment is well documented in patients with large B-cell lymphoma.²⁰ Our findings extend this knowledge to the context of brexu-cel treatment for MCL, where low platelet counts—reflecting compromised bone marrow reserve and endothelial activation—are associated with increased toxicity and reduced survival.

Regarding in-vivo expansion monitoring, our results corroborate the association between CAR T-cell expansion and PFS previously established by Herbaux et al.,⁸ albeit in a three-time larger cohort. Furthermore, our study confirms the dismal outcome of patients who do not respond to

brexu-cel treatment and, for the first time, demonstrates how in-vivo monitoring of CAR T cells can identify this ultra-high-risk population early on. Notably, the cut-off for CAR T-cell expansion associated with PFS differs significantly between our study and that of Herbaux et al. (C_{MAX} : 132.9 CAR+/μL in our cohort vs. 60 CAR+/μL in Herbaux et al). This discrepancy underscores the need to standardize techniques and harmonize results across studies to ensure that expansion data are incorporated in patient stratification. As for toxicity, our work is consistent with that of Hamilton et al.¹⁰ correlating greater in-vivo expansion with a higher incidence of CRS.

Among the baseline characteristics, the administration of bridging therapy was significantly linked to a reduced expansion. However, the variety of treatments utilized as bridging therapy limits our ability to link reduced expansion to a specific strategy and suggests that further research is required to clarify this relationship. Given the impact of refractoriness to covalent BTKi on survival and the experimental data suggesting a beneficial effect of BTKi in terms of in-vivo CAR T-cell expansion,²¹ the design of studies incorporating non-covalent BTK inhibitors, such as pirtobrutinib,²² as a bridging strategy will be of particular interest.

Considering the continuous pattern of relapse, risk stratification will be crucial for allocating high-risk patients to consolidation strategies, such as allogeneic transplantation or other maintenance therapies. Bispecific antibody treatments may represent a therapeutic opportunity also in MCL, given the impressive results recently demonstrated with Glofitamab.²³

In conclusion, (i) BTKi refractoriness emerges as a critical issue for patients treated with brexu-cel; (ii) the optimal strategy for bridging in MCL remains unclear; (iii) in-vivo monitoring of CAR T-cell expansion using multiparametric flow cytometry has proven feasible and, together with other clinical factor, could inform patient risk stratification.

AUTHOR CONTRIBUTIONS

Conception and design: Federico Stella, Annalisa Chiappella, Martina Magni, Cristiana Carniti, Paolo Corradini. Provision of study materials or patients: All authors; Collection and assembly of data: Federico Stella, Annalisa Chiappella, Martina Magni, Silva Ljevar, Cristiana Carniti, Paolo Corradini. Data analysis and interpretation: Federico Stella, Annalisa Chiappella, Silva Ljevar, Cristiana Carniti, Paolo Corradini. Funding acquisition: Paolo Corradini. Manuscript writing: All authors. Final approval of manuscript: All authors.

AFFILIATIONS

¹Hematology, School of Medicine, Università degli Studi di Milano, Milan, Italy

²Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

⁴Department of Oncology/Hematology, IRCCS Humanitas Research Hospital, Milan, Italy

⁵Dipartimento Oncologico “La Maddalena”, UOC di Oncoematologia e TMO, Palermo, Italy

⁶SOD Terapie Cellulari e Medicina Trasfusionale, AAD Trapianto di midollo osseo, Ospedale Careggi, Florence, Italy

⁷Department of Data Science, Unit of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

⁸Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

⁹Unit of Blood Disease and Bone Marrow Transplantation, Unit of Hematology, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy

¹⁰Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy

¹¹Division of Hematology—AO S. Croce e Carle, Cuneo and Laboratory of Blood Tumor Immunology, Molecular Biotechnology Center "Guido Tarone", University of Torino, Torino, Italy

¹²Dipartimento di Ematologia e trapianto di midollo, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

¹³IRCCS Ospedale San Raffaele Milano, Milan, Italy

¹⁴SC Ematologia, AOU Città della Salute e della Scienza, Torino, Italy

¹⁵Haematology and Stem Cell Transplantation Unit, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy

¹⁶Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine (DIMI), University of Verona, Verona, Italy

¹⁷Department of Molecular Medicine, University of Pavia, Pavia, Italy

¹⁸Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

¹⁹Hematology Unit, San Bortolo Hospital, Vicenza, Italy

²⁰Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy

ACKNOWLEDGEMENTS

We thank Sonia Perticone and the trial office of the Fondazione Italiana Linfomi for management of the study. We thank Anna Fedina for the data export.

FUNDING INFORMATION

This study is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, 'Associazione Italiana contro le Leucemie-linfomi e mieloma' (AIL) Milano; 'Società Italiana di Ematologia'; Italian Ministry of Health #PNC-E3-2022-23 683 269-PNC-HLS-TA and #PNRR-MAD-2022-12 376 059. The research leading to these results has received funding from AIRC under IG 2024—ID. 31 005 project—Paolo Corradini Paolo.

CONFLICT OF INTEREST STATEMENT

Federico Stella—nothing to disclose; Annalisa Chiappella—reports other support from Gilead Sciences, Ideogen, Roche, Secura Bio, Takeda, AbbVie, Eli Lilly and Company, Incyte, Janssen-Cilag, and Novartis outside the submitted work; Martina Magni—nothing to disclose; Francesca Bonifazi—fees from Novartis and Kite-Gilead; Chiara De Philippis—nothing to disclose; Maurizio Musso—advisory board Kite/Gilead; Novartis; BMS. Speakers bureau: Kite/Gilead; Novartis; BMS; Ilaria Cutini—nothing to disclose, Silva Ljevar—nothing to disclose; Anna Maria Barbui—nothing to disclose; Mirko Farina—nothing to disclose; Massimo Martino—advisory board Kite/Gilead; Novartis; BMS. Speakers bureau: Kite/Gilead; Novartis; BMS; Massimo Massaia—nothing to disclose; Giovanni Grillo—nothing to disclose; Piera Angelillo—Incyte, Barbara Botto—nothing to disclose, Francesca Patriarca—Sanofi, Menarini, Novartis, BMS; Mauro Krampera—Advisory boards and honoraria for lectures/educational events: Kite Gilead, Novartis, Janssen-Cilag, Incyte, AbbVie, BeiGene, Menarini StemLine, Roche; Luca Arcaini—Honoraria: EUSA Pharma, Novartis.

Advisory boards for Roche, Janssen-Cilag, Verastem, Incyte, EUSA Pharma, Celgene/Bristol Myers Squibb, Kite/Gilead, ADC Therapeutics, Novartis; Maria Chiara Tisi—personal fees from Novartis, Gilead, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Sobi and Incyte; Pierluigi Zinzani—Consultant: MSD, Eusapharma, Novartis; Advisory boards: ADC Therapeutics, Astrazeneca, BeiGene, BMS, Celltrion, Eusapharma, Gilead, Incyte, Janssen-Cilag, KyowaKirin, MSD, Novartis, Roche, Sandoz, SecuraBio, Servier, Takeda; speakers bureau: Astrazeneca, Beigene, BMS, Celltrion, Eusapharma, Gilead, Incyte, Janssen-Cilag, Kyowa-Kirin, MSD, Novartis, Roche, Servier, Takeda; Federica Sorà—nothing to disclose; Stefania Bramanti—Speaker bureau: Bms; Gilead, Novartis, Advisory Board Novartis, Travel Accomodation Novartis, Roche, Martina Pennisi—nothing to disclose, Cristiana Carniti—nothing to disclose, Paolo Corradini—Advisory boards: AbbVie, ADC Therapeutics, Amgen, BeiGene, Celgene, Daiichi Sankyo, Gilead/Kite, GSK, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda; honoraria for lectures: AbbVie, Amgen, Celgene, Gilead/Kite, Janssen, Novartis, Roche, Sanofi, Takeda.

DATA AVAILABILITY STATEMENT

For data sharing and any further information, please contact the corresponding author.

ORCID

Federico Stella  <https://orcid.org/0000-0003-3401-1309>

Annalisa Chiappella  <https://orcid.org/0000-0002-2977-0098>

Martina Magni  <https://orcid.org/0000-0001-9458-5836>

Francesca Bonifazi  <https://orcid.org/0000-0003-1544-9911>

Ilaria Cutini  <https://orcid.org/0000-0003-3721-0004>

Luca Arcaini  <https://orcid.org/0000-0002-9504-991X>

Pierluigi Zinzani  <https://orcid.org/0000-0002-2112-2651>

Cristiana Carniti  <https://orcid.org/0000-0003-1039-1757>

Paolo Corradini  <https://orcid.org/0000-0002-9186-1353>

REFERENCES

- Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. *Blood*. 2016;127(12):1559–63. <https://ashpublications.org/blood/article/127/12/1559/35048/Postibrutinib-outcomes-in-patients-with-mantle>
- Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. *J Clin Oncol*. 2016;34(11):1256–69. <https://doi.org/10.1200/JCO.2015.63.5904>
- Jain P, Romaguera J, Srour SA, Lee HJ, Hagemester F, Westin J, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). *Br J Haematol*. 2018;182(3):404–11. <https://doi.org/10.1111/bjh.15411>
- Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*. 2020;382(14):1331–42. <https://doi.org/10.1056/NEJMoa1914347>
- Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed/

- refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. *J Clin Oncol.* 2023;41(3):555–67. <https://doi.org/10.1200/JCO.21.02370>
6. Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. *Blood Adv.* 2022;6(12):3606–10. <https://ashpublications.org/bloodadvances/article/6/12/3606/484368/Real-world-evidence-of-brexucabtagene-autoleucel>
 7. Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. *J Clin Oncol.* 2023;41(14):2594–606. <https://doi.org/10.1200/JCO.22.01797>
 8. Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, et al. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. *Haematologica.* 2024;109:3745–50.
 9. O'Reilly MA, Wilson W, Burns D, Kuhn A, Seymour F, Uttenthal B, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis. *Hemasphere.* 2024;8(6):e87. <https://doi.org/10.1002/hem3.87>
 10. Hamilton MP, Craig E, Gentile Sanchez C, Mina A, Tamaresis J, Kirmani N, et al. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. *Blood Adv.* 2024;8(12):3314–26. <https://ashpublications.org/bloodadvances/article/8/12/3314/515342/CAR19-monitoring-by-peripheral-blood>
 11. Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, et al. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. *Blood Adv.* 2023;7(16):4576–85. <https://ashpublications.org/bloodadvances/article/7/16/4576/496262/Time-to-progression-of-disease-and-outcomes-with>
 12. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med.* 2013;369(6):507–16. <https://doi.org/10.1056/NEJMoal306220>
 13. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugo classification. *J Clin Oncol.* 2014;32(27):3059–67.
 14. Lee DW, Santomaso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biol Blood Marrow Transplant.* 2019;25(4):625–38. <https://doi.org/10.1016/j.bbmt.2018.12.758>
 15. Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. *Blood.* 2023;142(10):865–77.
 16. Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. *Blood.* 2021;138(24):2499–513.
 17. Monfrini C, Stella F, Aragona V, Magni M, Ljevar S, Vella C, et al. Phenotypic composition of commercial anti-CD19 CAR T cells affects in-vivo expansion and disease response in patients with large B-cell lymphoma. *Clin Cancer Res.* 2022;28:3378–86. <https://doi.org/10.1158/1078-0432.CCR-22-0164>
 18. Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. *Br J Haematol.* 2023;202(4):749–59. <https://doi.org/10.1111/bjh.18519>
 19. Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomis. *Lancet.* 2024;403(10441):2293–306. <https://linkinghub.elsevier.com/retrieve/pii/S0140673624001843>
 20. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. *J Clin Oncol.* 2020;38(27):3119–28. <https://doi.org/10.1200/JCO.19.02104>
 21. Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. *Cancer Cell Int.* 2024;42(8):1319–25. <https://linkinghub.elsevier.com/retrieve/pii/S1535610824002678>
 22. Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. *J Clin Oncol.* 2023;41(24):3988–97. <https://doi.org/10.1200/JCO.23.00562>
 23. Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trněný M, et al. Glofitamab in relapsed/refractory mantle cell lymphoma: results from a phase I/II study. *J Clin Oncol.* 2024;JCO2302470. <https://doi.org/10.1200/JCO.23.02470>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Stella F, Chiappella A, Magni M, Bonifazi F, De Philippis C, Musso M, et al. Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study. *Br J Haematol.* 2025;206(2):644–651. <https://doi.org/10.1111/bjh.19961>